



## QM 1: Performance Status




## QM 2: Initial Evaluation: PSA, T Stage, Gleason Score and Risk Group


\*Still collect data on prostate surgery patients




## **QM 3: Imaging/Staging for High or Very High Risk**




## **QM 4: Discussion of Treatment Options for Intermediate Risk**




## QM 5: Quality of Life Assessment at Time of Consult



## QM 6: Enrolled Clinical Trial



## QM 7: Use of 3D or IMRT



**EDIT:** This decision tree was changed due to a conversation with ASTRO. The QM will now be evaluated with all planning types on a Pass/Fail level, while the percentage of IMRT/3D plans will be a secondary evaluation

### Secondary Analysis


Collect:

Total # of IMRT Plans per Site

Total # of 3D Plans per Site


Secondary analysis data should be presented as a percentage of plans that utilized IMRT out of all the IMRT and 3D plans per site

## QM 8: Dose-Volume Histogram Evaluation




## QM 9: Androgen Deprivation Therapy for High Risk Disease

\*Still collect data on prostate surgery patients




## QM 10: Androgen Deprivation Therapy for Intermediate Risk

\*Still collect data on prostate surgery patients




# QM 11: Daily Target Localization




## QM 12: Comprehensive Treatment for High Risk


Comprehensive Treatment




## QM 13: Immobilization



## QM 14: Dose for Conventional Fractionation Scheme




## QM 15: Appropriate Dose for Post-Prostatectomy




Exclusions	Fails	Pass
Prostate patients who have not had surgery	Dose/Fx lower than 180 cGy/Fx for any of the EBRT plans	Patients with a Total EBRT perscription between 6000 cGy and 7400 cGy <b>that also have</b> a Dose/Fx between 180-200 cGy/Fx <b>per</b> EBRT plan
Had LDR	Dose prescription for all EBRT plans combined less than 6000cGy	Green: $6400 < \text{Dose} \leq 7200$ Yellow: $6000 \leq \text{Dose} \leq 6400$ Red: $\text{Dose} > 7200$
Had HDR	Dose prescription for all EBRT plans combined more than 7400 cGy	
HypoFractionated Plans (Dose/Fx higher than 200 cGy/Fx) for any of the EBRT plans		
On a Clinical Trial		


# QM 23: Survivorship Care Plan




## QM 17A: Post-Implant Dosimetry Evaluation




## QM 17B: Timing of Post-Implant Dosimetry Within 60 Days



## QM 18: Follow-up Intervals



## QM 19: Quality of Life Assessment at Follow-Up



Only the patients who received follow-ups with an “Alive” patient status will be evaluated for this QM. Please refer to QM 18 for F/U information.

QM requires a QoL at every F/U, so QM should be evaluated PER PATIENT.  
(See LUNG QM 22.)

### 1. Per patient

ex. Patient 1 has:

F/U1 – Yes QoL

F/U2 – Yes QoL

Score = 1

ex. Patient 2 has:

F/U1 – Yes QoL,

F/U2 – No QoL

Score = 0

# Evaluation 1: [QM] Toxicity Affirmation - Prostate

- Calculate using the numerator/denominator below to calculate and report per:


- Patient
- Institution

$$1 - \frac{\text{# of OTV and Follow-up notes w/ } \textit{Toxicity} \text{ not initialized}}{\text{total number of OTV and Follow-up notes}}$$

# PROSTATE TOXICITY QM 2 – Toxicity Grading Rate

(All OTV and Follow-up Notes)


Only evaluate OTV and FOLLOW-UP NOTES. NURSE'S NOTES and COMPLETION of THERAPY NOTES are excluded.



# PROSTATE TOXICITY QM 2 – Toxicity Grading Rate

(All OTV and Follow-up Notes)

Only evaluate OTV and FOLLOW-UP NOTES. NURSE'S NOTES and COMPLETION of THERAPY NOTES are excluded.



<b>GU Tox</b>	<b>GI Tox</b>	<b>Other Tox</b>
Cystitis	Constipation	Desquamation
Dysuria	Diarrhea	Erythema
Erectile dysfunction	Hematochezia	Fatigue
Frequency	Nausea	Skin Hypo/Hyperpigment.
Nocturia	Proctitis	Other toxicity
Urgency	Small bowel obstruction	
	Stomach ulcer	
	Vomit	

## QM 24: Baseline Bone Health Assessment

